Glucagon-like pepetide-1 receptor agonist suggests novel therapeutic options for hypothalamic obesity

IF 3.1 3区医学 Q2 ENDOCRINOLOGY & METABOLISM

Journal of Diabetes Investigation Pub Date : 2024-12-11 DOI:10.1111/jdi.14372

Wanlu Ma, Bo Zhang, Xiaoping Chen

引用次数: 0

Abstract

We briefly summarizes the mechanism of GLP-1RA therapy in HO both in rodents and in humans. We also summarized the clinical trials and case reports of GLP-1RA therapy in HO, especially the more and more often used semaglutide. We are hoping the therapy of GLP-1RA in HO will arouse more attention from clinicians in the future.

Abstract Image

查看原文本刊更多论文

胰高血糖素样肽-1受体激动剂为下丘脑肥胖提供了新的治疗选择。

我们简要总结GLP-1RA治疗啮齿动物和人类HO的机制。我们还总结了GLP-1RA治疗HO的临床试验和病例报告，特别是越来越多地被使用的西马鲁肽。我们希望GLP-1RA在HO中的治疗能在未来引起临床医生更多的关注。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Journal of Diabetes Investigation ENDOCRINOLOGY & METABOLISM-

CiteScore

6.50

自引率

9.40%

发文量

218

审稿时长

6-12 weeks

期刊介绍： Journal of Diabetes Investigation is your core diabetes journal from Asia; the official journal of the Asian Association for the Study of Diabetes (AASD). The journal publishes original research, country reports, commentaries, reviews, mini-reviews, case reports, letters, as well as editorials and news. Embracing clinical and experimental research in diabetes and related areas, the Journal of Diabetes Investigation includes aspects of prevention, treatment, as well as molecular aspects and pathophysiology. Translational research focused on the exchange of ideas between clinicians and researchers is also welcome. Journal of Diabetes Investigation is indexed by Science Citation Index Expanded (SCIE).